Clinical studies in various cancers, such as NSCLC and melanoma, have shown that patients whose tumors are characterized by both high PD-L1 expression and high CD8+ density tend to experience better responses to ICIs [38,39,40]. The gene discussed is CD8A; the disease is cancer.